Conexeu Sciences (NASDAQ:CNXU) Upgraded at Zacks Research

Conexeu Sciences (NASDAQ:CNXU) was upgraded by analysts at Zacks Research to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other research firms have also weighed in on CNXU. HC Wainwright assumed coverage on shares of Conexeu Sciences in a research report on Monday, June 22nd. They issued a “buy” rating and a $20.00 price target for the company. Wall Street Zen upgraded shares of Conexeu Sciences to a “hold” rating in a research report on Saturday, May 30th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Conexeu Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Conexeu Sciences Stock Up 6.6%

Shares of NASDAQ:CNXU opened at $10.92 on Monday. Conexeu Sciences has a 12-month low of $9.60 and a 12-month high of $18.79.

Conexeu Sciences (NASDAQ:CNXU) last released its earnings results on Monday, June 15th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Insider Activity

In other Conexeu Sciences news, Director Lynn Sebastian Purcell bought 202,500 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average price of $0.80 per share, for a total transaction of $162,000.00. Following the completion of the transaction, the director owned 2,734,240 shares of the company’s stock, valued at $2,187,392. This trade represents a 8.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Key Stories Impacting Conexeu Sciences

Here are the key news stories impacting Conexeu Sciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $20 price target, signaling confidence in Conexeu Sciences despite near-term losses. Conexeu Sciences Free Report
• Positive Sentiment: The firm’s longer-term estimates turn sharply positive, with projected EPS of $1.02 for FY2028, $1.70 for FY2029, and $2.52 for FY2030, suggesting potential future earnings growth. Conexeu Sciences Free Report
• Neutral Sentiment: HC Wainwright’s near-term forecasts remain negative, including estimated losses of ($0.40) per share for FY2026 and ($0.53) for FY2027, which keeps investors focused on execution rather than current profitability. Conexeu Sciences Free Report

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.